The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis
Open accessAbstract
Despite aggressive antibiotic therapy, bronchopulmonary colonization by Pseudomonas aeruginosa causes persistent morbidity and mortality in cystic fibrosis (CF). Chronic P. aeruginosa infection in the CF lung is associated with structured, antibiotic-tolerant bacterial aggregates known as biofilms. We have demonstrated the effects of non-bactericidal, low-dose nitric oxide (NO), a signaling molecule that induces biofilm dispersal, as a novel adjunctive therapy for P. aeruginosa biofilm infection in CF in an ex vivo model and a proof-of-concept double-blind clinical trial. Submicromolar NO concentrations alone caused disruption of biofilms within ex vivo CF sputum and a statistically significant decrease in ex vivo biofilm tolerance to tobramycin and tobramycin combined with ceftazidime. In the 12-patient randomized clinical trial, 10 ppm NO inhalation caused significant reduction in P. aeruginosa biofilm aggregates compared with placebo across 7 days of treatment. Our results suggest a benefit of using low-dose NO as adjunctive therapy to enhance the efficacy of antibiotics used to treat acute P. aeruginosa exacerbations in CF. Strategies to induce the disruption of biofilms have the potential to overcome biofilm-associated antibiotic tolerance in CF and other biofilm-related diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinically, NO-based dispersal remains a practical adjunct. It can resensitize biofilm aggregates, and early trials and translational reviews outline guidance on donor selection, delivery methods, and endpoints [134,291,292].”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [134]
In the citing paper
“Clinically, NO-triggered dispersal remains the best validated PDE activation approach. It transiently lowers c-di-GMP and enhances antibiotic activity, and is supported by controlled CF trials and progress in donor chemistry and delivery [134,278].”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Should we stay or should we go: mechanisms and ecological consequences for biofilm dispersal
McDougald, D., Rice, S. A., Barraud, N., Steinberg, P. D., & Kjelleberg, S. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2695 · Cited by 881
Self-citationBryan, N. S., Rassaf, T., Maloney, R. E., Rodriguez, C. M., Saijo, F., Rodriguez, J. R., & Feelisch, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306706101 · Cited by 400
Self-citationBarraud, N., Storey, M. V., Moore, Z. P., Webb, J. S., Rice, S. A., & Kjelleberg, S. (2009) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2009.00098.x · Cited by 289
Self-citationDeppisch, C., Herrmann, G., Graepler-Mainka, U., Wirtz, H., Heyder, S., Engel, C., Marschal, M., Miller, C. C., & Riethmüller, J. (2016) · Infection · doi:10.1007/s15010-016-0879-x · Cited by 115
Cited by
Targeting microbial biofilms: current and prospective therapeutic strategies
Koo, H., Allan, R. N., Howlin, R. P., Stoodley, P., & Hall-Stoodley, L. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.99 · Cited by 1,800
Self-citationPseudomonas aeruginosa Biofilms
Thi, M. T. T., Wibowo, D., & Rehm, B. H. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228671 · Cited by 911
Challenges of intervention, treatment, and antibiotic resistance of biofilm-forming microorganisms
Gebreyohannes, G., Nyerere, A., Bii, C., & Sbhatu, D. B. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02192 · Cited by 414
Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections
Ma, Y., Wang, C., Li, Y., Li, J., Wan, Q., Chen, J., Tay, F. R., & Niu, L. (2020) · Advanced Science · doi:10.1002/advs.201901872 · Cited by 314
Mai-Prochnow, A., Zhou, R., Zhang, T., Ostrikov, K., Mugunthan, S., Rice, S. A., & Cullen, P. J. (2021) · npj Biofilms and Microbiomes · doi:10.1038/s41522-020-00180-6 · Cited by 258
Self-citation
Metadata
- Authors
- Howlin, R. P., Cathie, K., Hall-Stoodley, L., Cornelius, V., Duignan, C., Allan, R. N., Fernandez, B. O., Barraud, N., Bruce, K. D., Jefferies, J., Kelso, M., Kjelleberg, S., Rice, S. A., Rogers, G. B., Pink, S., Smith, C., Sukhtankar, P. S., Salib, R., Legg, J., Carroll, M., Daniels, T., Feelisch, M., Stoodley, P., Clarke, S. C., Connett, G., Faust, S. N., & Webb, J. S.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 25
- Issue
- 9
- Pages
- 2104-2116
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2724107058
- Cited by
- 209
- References
- 4
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis. https://app.cochat.ai/papers/10.1016/j.ymthe.2017.06.021
- The paper
- Howlin, R. P., Cathie, K., Hall-Stoodley, L., Cornelius, V., Duignan, C., Allan, R. N., Fernandez, B. O., Barraud, N., Bruce, K. D., Jefferies, J., Kelso, M., Kjelleberg, S., Rice, S. A., Rogers, G. B., Pink, S., Smith, C., Sukhtankar, P. S., Salib, R., Legg, J., . . . Webb, J. S. (2017). Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2017.06.021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.